Drug Profile
Lonapegsomatropin - Ascendis Pharma
Alternative Names: ACP 001; ACP 011; Lonapegsomatropin-tcgd; SKYTROFA; TransCon growth hormone; TransCon hGH; TransCon PEG growth hormone; TransCon PEG hGH; TransCon PEG somatropinLatest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator Ascendis Pharma
- Developer Ascendis Pharma; VISEN Pharmaceuticals
- Class Growth hormones; Hormonal replacements; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Somatotropin deficiency
- Phase II Turner's syndrome
Most Recent Events
- 08 Jan 2024 Ascendis Pharma and Vector Pharma enter into a distribution agreement to commercialize Skytrofa™ in the Gulf Cooperation Council (GCC) countries
- 07 Jan 2024 Lonapegsomatropin licensed to Specialised Therapeutics for commercialization in Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam
- 07 Jan 2024 Ascendis Pharma plans to submit sBLA to US FDA for Somatotropin deficiency in the second quarter of 2024